Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the acute leukemia working party of the european society for blood and marrow transplantation - Université de Lille Accéder directement au contenu
Article Dans Une Revue Haematologica Année : 2020

Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the acute leukemia working party of the european society for blood and marrow transplantation

Kazimierz Halaburda
  • Fonction : Auteur
Myriam Labopin
  • Fonction : Auteur
Audrey Mailhol
  • Fonction : Auteur
Gerard Socie
  • Fonction : Auteur
Charles Craddock
  • Fonction : Auteur
Mahmoud Aljurf
  • Fonction : Auteur
Dietrich Beelen
  • Fonction : Auteur
Jan J. Cornelissen
  • Fonction : Auteur
Jean-Henri Bourhis
  • Fonction : Auteur
Helene Labussiere-Wallet
  • Fonction : Auteur
Didier Blaise
Tobias Gedde-Dahl
  • Fonction : Auteur
Maria H. Gilleece
  • Fonction : Auteur
Ghulam Mufti
  • Fonction : Auteur
Jordi Esteve
  • Fonction : Auteur
Mohamad Mohty
  • Fonction : Auteur
Arnon Nagler
  • Fonction : Auteur

Résumé

Core binding factor acute myeloid leukemia (AML) comprises two subtypes with distinct cytogenetic abnormalities of either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). Since long-term response to chemotherapy in these leukemias is relatively good, allogeneic hematopoietic stem cell transplantation is considered in patients who relapse and achieve second complete remission. To evaluate the outcomes of allogeneic transplantation in this indication, we studied 631 patients reported to the European Society for Blood and Marrow Transplantation Registry between the years 2000 and 2014. Leukemia-free survival probabilities at two and five years were 59.1% and 54.1%, while overall survival probabilities were 65% and 58.2%, respectively. The incidence of relapse and risk of non-relapse mortality at the same time points were 19.8% and 22.5% for relapse and 20.9% and 23.3% for non-relapse mortality, respectively. The most important adverse factors influencing leukemia-free and overall survival were: leukemia with t(8;21), presence of three or more additional chromosomal abnormalities, and Karnofsky performance score <80. Relapse risk was increased in t(8;21) leukemia and associated with additional cytogenetic abnormalities as well as reduced intensity conditioning. Measurable residual disease in molecular evaluation before transplantation was associated with increased risk of relapse and inferior leukemia-free survival.
Fichier principal
Vignette du fichier
9449-Article Text-69767-1-10-20200725.pdf (3.21 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04426662 , version 1 (30-01-2024)

Licence

Identifiants

Citer

Kazimierz Halaburda, Myriam Labopin, Audrey Mailhol, Gerard Socie, Charles Craddock, et al.. Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the acute leukemia working party of the european society for blood and marrow transplantation. Haematologica, 2020, Haematologica, 105, ⟨10.3324/haematol.2019.222810⟩. ⟨hal-04426662⟩

Collections

RIIP UNIV-LILLE
13 Consultations
5 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More